BioArctic stock

BIOA.B · Nasdaq Stockholm · SEK

Compare BioArctic
kr 300.60Change from previous close: −1.83%Absolute change: −kr 5.60

Close · November 20, 2026

Price history

+5.70% over the period

1 year: from kr 284.40 (November 20, 2025) to kr 300.60 (November 20, 2026), +5.70%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026kr 300.60
October 30, 2026kr 317.20
September 30, 2026kr 310.40
August 31, 2026kr 318.40
July 31, 2026kr 325.00
June 30, 2026kr 329.20
May 29, 2026kr 352.40
April 30, 2026kr 323.80
March 31, 2026kr 320.00
February 27, 2026kr 308.80
January 30, 2026kr 319.00
December 30, 2025kr 310.80
November 28, 2025kr 304.60
November 20, 2025kr 284.40

At a glance

  • The company

    Develops biological drugs, primarily antibodies, for central nervous system disorders including Alzheimer's, Parkinson's and ALS

  • Latest results

    Quarter to June 30, 2026 · EPS -kr 0.13 (estimate -kr 0.77)

TickerLandia's take on BioArctic

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowkr 275.80
52-wk highkr 364.40

−17.51% from the 52-week high

Analysts · 3 analysts

Average targetkr 314.00+4.46% vs. price

Buy 2 · Hold 1 · Sell 0

TickerLandia Fingerprint: BioArctic

Compared with similar companies: very high price.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

BioArctic is cheaper than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), BioArctic's P/E today is 26.1, below the median of its last 5 fiscal years (94.9; between 18.9 and 116.7 from 2017 to 2025). BioArctic's P/E (trailing 12 months): 259.5, +1,331% against the median of a group of 9 similar companies (18.1).

P/E compared with its history

Compared with 9 similar companies

BioArctic's metrics compared with similar companies
MetricBioArcticPosition in the groupBand
P/E (trailing 12 months)259.5High
Forward P/E105.6High
Operating margin19.6%Middle
ROE5.2%Low
Debt/equity0.04Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: BioArctic. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

kr 247.53M

Latest quarter · Q2 2026

Net income

-kr 11.17M

Latest quarter · Q2 2026

Quarterly net margin

-4.5%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
kr 27.17B
P/E
259.5
EPS
kr 1.18
Volume
72.62K
Daily trading
€2.87M
Dividend yield
0.67%
Last ex-dividend on May 29, 2026

How BioArctic is changing

All results
  • Revenue grew 98.3% a year on average over the last 5 years

  • Operating margin rose from −3.5% to 68.4%

  • Profits turn into cash: free cash flow equal to 128% of net income

Returns

BioArctic returns with dividends

kr 1,000 invested in BioArctic 5 years ago, on November 22, 2021, would be worth kr 2,515 today with dividends reinvested: +151.50% in total, +20.28% per year. On price alone it would be kr 2,501 (+150.08%).

PeriodBioArctickr 1,000 becomes
1 month+0.20%kr 1,002
6 months−6.59%kr 934
Year to date−3.28%kr 967
1 year+6.30%kr 1,063
3 years+28.10%kr 1,281
5 years+151.50%kr 2,515

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

BioArctic: technical analysis

BioArctic is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 20.4% below its all-time closing high (kr 377.80, June 12, 2023).

Trend
Downward
RSI (14 sessions)
43
Between 30 and 70
vs 200-session average
−5.01%

Active signals

  • The price is moving in an unusually narrow range compared with the last year.

    since November 16, 2026

Support and resistance

Price areas where BioArctic has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistancekr 327.35+8.90%4 touches, last on October 29, 2026
  2. Resistancekr 316.20+5.19%3 touches, last on November 10, 2026
  3. Resistancekr 304.12+1.17%5 touches, last on May 19, 2026
  4. Last pricekr 300.60
  5. Supportkr 292.27−2.77%3 touches, last on July 17, 2026
  6. Supportkr 284.70−5.29%4 touches, last on November 3, 2026
  7. Supportkr 276.70−7.95%2 touches, last on June 10, 2026

Volatility and risk

Volatility (60 sessions, annualised)
29.4%
Largest fall in the last year
−22.94%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

BioArctic: seasonality

Average monthly price change over 9 years

+1.9%Jan−2.9%Feb−10.0%Mar+0.9%Apr+4.9%May+2.3%Jun+38.6%Jul+4.9%Aug+21.8%Sep−5.6%Oct+8.2%Nov+3.1%Dec

Over the last 9 years, the strongest month for BioArctic has been July: +38.59% on average, positive in 6 years out of 9. The weakest has been March: −9.95% on average, positive in 3 years out of 9. November, the current month, has been positive in 7 years out of 9 (+8.22% on average).

Show chart data
MonthAverageMedianPositive years
January+1.93%+4.21%6 of 9
February−2.88%−7.46%2 of 9
March−9.95%−12.71%3 of 9
April+0.85%+1.28%6 of 9
May+4.91%+3.71%5 of 9
June+2.33%−2.20%3 of 9
July+38.59%+7.02%6 of 9
August+4.90%+3.11%6 of 9
September+21.76%−2.25%3 of 9
October−5.59%−7.32%3 of 9
November+8.22%+4.03%7 of 9
December+3.11%+2.98%7 of 9

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

BioArctic and its competitors

Employing 150 people, the Stockholm-based biotech develops antibody drugs aimed at brain and nerve diseases. Its most advanced asset is lecanemab, which it offers as an intravenous treatment while developing a subcutaneous version, and a further lecanemab study is in Phase 3 testing for patients before symptoms appear. Other programmes target Alzheimer's, Parkinson's and ALS, and preclinical and research-stage projects cover additional central nervous system targets.

Headquarters
Stockholm, Sweden
Employees
150
Founded
2000
Chief executive
Gunilla Osswald
BioArctic and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
BioArcticBIOA.B$2.66B19.6%259.5−6.59%
Bavarian NordicBAVA$2.72B18.1%12.7+24.00%
Zealand PharmaZEAL$2.05B59.0%4.76−33.57%
Lakefront BiotherapeuticsLKFT$2.19B57.5%2.53+29.28%
CamurusCAMX$4.32B37.4%58.7+37.97%
IdorsiaIDIA$1.26B-68.4%—−10.26%

Same industry or related industries, similar size. Compare BioArctic with its competitors · Full profile